低分子肝素对重度子痫前期合并胎儿生长受限胎盘病理及HO-1表达的影响

doi:10.6040/j.issn.1671-7554.0.2014.281

摘要/Abstract

摘要： 目的探讨低分子肝素干预对重度子痫前期合并胎儿生长受限(FGR)患者胎盘病理及血红素氧合酶-1(HO-1)表达的影响.方法 97例患者随机分为肝素治疗组(44例)及常规治疗组(53例),7 d为一疗程,观察胎盘质量; HE染色观察胎盘绒毛滋养细胞,绒毛间纤维素样渗出、坏死及绒毛血管减少、闭塞及梗死灶情况;免疫组化检测胎盘HO-1表达.结果肝素治疗组胎盘质量均增加,与常规治疗组比较差异有统计学意义(P<0.05).HE染色结果显示,常规治疗组胎盘形态学观察缺血缺氧较肝素治疗组更明显(P<0.05).免疫组化检测肝素治疗组中HO-1表达更强(P<0.05).结论低分子肝素治疗可改善重度子痫前期合并FGR胎盘的绒毛形态,改善胎盘的缺血、缺氧表现;可提高HO-1的表达,扩张血管,保护胎盘细胞免受氧化损失,促进胎儿生长发育.

关键词: 胎盘病理, 血红素氧合酶-1, 重度子痫前期, 胎儿生长受限, 低分子肝素, 胎盘质量

Abstract: Objective To investigate the effect of low molecular weight heparin (LMWH) on severe preeclampsia complicated with fetal growth restriction (FGR) and expression of hemeoxygenase-1(HO-1). Methods A total of 97 cases were randomized into LMWH group (n=44) and control group (n=53). After 7-day treatment, changes of placental weight were observed. Villous stromal cells, fibrinoid effusion and necrosis, decrease, obstruction and infarction of villus blood vessels were observed with HE staining. HO-1 expression was detected with immunohistochemical method. Results The placental weight increased significantly in LMWH group (P<0.05). Hypoxic-ischemia changes of placenta decreased markedly in LMWH group (P<0.05). The HO-1 protein expression increased remarkably in LMWH group (P<0.05). Conclusion LMWH can improve villi morphology and ischemia hypoxia of placenta for severe preeclampsia complicated with FGR. Additionally, it can increase the expression of HO-1, dilate vessels, and protect the placenta from being oxidized, thus promoting the fetal growth.

Key words: Severe preeclampsia, Placental pathology, Fetal growth restriction, Low molecular weight heparin, Hemeoxygenase-1, Placenta weight

中图分类号:

R714.24

段颜, 刘媛媛. 低分子肝素对重度子痫前期合并胎儿生长受限胎盘病理及HO-1表达的影响[J]. 山东大学学报（医学版）, 2014, 52(11): 77-80.

DUAN Yan, LIU Yuanyuan. Effect of LMWH on severe preeclampsia complicated with FGR and HO-1 expression[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 77-80.

参考文献

[1] 董熙萍, 徐永萍. 低分子肝素对胎儿生长受限的治疗作用[J]. 实用妇产科杂志, 2006, 22(9): 531-534. DONG Xiping, XU Yongping. The effects of low molecular weight heparin on fetal growth restriction[J]. Journal of Practical Obstetrics and Gynecology, 2006, 22(9): 531-534.
[2] 谢家凤, 刘健玲, 张锦英,等. 低分子肝素治疗子痫前期合并胎儿生长受限的疗效观察[J]. 中国妇幼保健, 2009, 24(7): 917-919. XIE Jiafeng, LIU Jianling, ZHANG Jinying, et al. Effect of low molecular heparin on preeclampsia and fetal growth restriction[J]. Maternal and Child Health Care of China, 2009, 24(7): 917-919.
[3] DIppolito S, Ortiz A S, Veglia M, et al. Low molecular weight heparin in obstetric care: a review of the literature[J]. Reprod Sci, 2011,18 (7): 602-613.
[4] Kupferminc M, Rimon E, Many A, et al. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophili[J]. Blood Coagul Fibrinolysis, 2011, 22 (2): 123-126.
[5] 于燕, 任利容, 张锐, 等. 低分子肝素治疗早发型重度子痫前期的临床分析[J]. 中国妇幼保健, 2012, 27(5): 663-665. YU Yan, REN Lirong, ZHANG Rui, et al. The clinical analysis of treating early onset severe pre- eclampsia by the low molecular heparin[J]. Maternal and Child Health Care of China, 2012, 27(5): 663-665.
[6] Conserva V, Muggiasca M, Arrigoni L, et al. Recurrence and severity of abnormal pregnancy outcome in patients treated by low-molecular-weight heparin: a prospective pilot study[J]. J Matern Fetal Neonatal Med, 2012, 25(8): 1467-1473.
[7] 乐杰. 妇产科学[M]. 7版. 北京: 人民卫生出版社, 2008: 92-98, 130-132.
[8] 陈宝丽, 王燕云, 李桂荣, 等. 重度子痫前期患者子宫胎盘病理学改变与围生儿结局相关性研究[J]. 中国妇幼保健, 2011, 26(30): 4659-4661. CHEN Baoli, WANG Yanyun, LI Guirong, et al. Study on the correlation between uteroplacental pathological change in patients with severe preeclampsia and perinatal outcome[J]. Maternal and Child Health Care of China, 2011, 26(30): 4659-4661.
[9] 王素梅, 唐卉, 黄玲玲, 等. 子痫前期与胎盘超微结构病理变化关系的研究[J]. 中国误诊学杂志, 2008, 8(6): 1341-1343. WANG Sumei, TANG Hui, HUANG Lingling, et al. The relationship between preeclampsia and placentalultrastructural pathological change[J]. Chinese Journal of Misdiagnostics, 2008, 8(6): 1341-1343.
[10] Vedmedovska N, Rrzeberga D, Teibe U, et al. Placental pathology in fetal growth restriction[J]. Eur J obstect Gynecol Reprod Biol, 2011, 155(1): 36-40.
[11] 李玲玲,张. 低分子肝素对胎儿生长受限患者胎盘超微结构及血管内皮生长因子表达的影响[J]. 中国妇产科临床杂志, 2012, 13(6): 440-442. LI Lingling, ZHANG Yan. Effects of low-molecular weight heparin on the placental ultrastructure and VEGF expression in cases with fetal growth restriction[J]. Chinese Journal of Clinical Obstetrics and Gynecology, 2012, 13(6): 440-442.
[12] Kaartokallio T, Klemetti M M, Timonen A, et al. Microsatellite polymorphism in the heme oxygenase-1 promoter is associated with nonsevere and late-onsetpreeclampsia[J]. Hypertension, 2014, 64(1): 172-177.
[13] Warrington J P, Coleman K, Skaggs C, et al. Heme oxygenase-1 promotes migration and β-epithelial Na+ channel expression in cytotrophoblasts and ischemic placentas[J]. Am J Physiol Regul Integr Comp Physiol, 2014, 306(9): R641-646.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed